150 related articles for article (PubMed ID: 29420962)
1. Activation of Serine One-Carbon Metabolism by Calcineurin Aβ1 Reduces Myocardial Hypertrophy and Improves Ventricular Function.
Padrón-Barthe L; Villalba-Orero M; Gómez-Salinero JM; Acín-Pérez R; Cogliati S; López-Olañeta M; Ortiz-Sánchez P; Bonzón-Kulichenko E; Vázquez J; García-Pavía P; Rosenthal N; Enríquez JA; Lara-Pezzi E
J Am Coll Cardiol; 2018 Feb; 71(6):654-667. PubMed ID: 29420962
[TBL] [Abstract][Full Text] [Related]
2. Calcineurin splicing variant calcineurin Aβ1 improves cardiac function after myocardial infarction without inducing hypertrophy.
Felkin LE; Narita T; Germack R; Shintani Y; Takahashi K; Sarathchandra P; López-Olañeta MM; Gómez-Salinero JM; Suzuki K; Barton PJ; Rosenthal N; Lara-Pezzi E
Circulation; 2011 Jun; 123(24):2838-47. PubMed ID: 21632490
[TBL] [Abstract][Full Text] [Related]
3. Induction of the calcineurin variant CnAβ1 after myocardial infarction reduces post-infarction ventricular remodelling by promoting infarct vascularization.
López-Olañeta MM; Villalba M; Gómez-Salinero JM; Jiménez-Borreguero LJ; Breckenridge R; Ortiz-Sánchez P; García-Pavía P; Ibáñez B; Lara-Pezzi E
Cardiovasc Res; 2014 Jun; 102(3):396-406. PubMed ID: 24667850
[TBL] [Abstract][Full Text] [Related]
4. Cardiac-Specific EPI64C Blunts Pressure Overload-Induced Cardiac Hypertrophy.
Zhu X; Fang J; Gong J; Guo JH; Zhao GN; Ji YX; Liu HY; Wei X; Li H
Hypertension; 2016 May; 67(5):866-77. PubMed ID: 27021007
[TBL] [Abstract][Full Text] [Related]
5. Carabin protects against cardiac hypertrophy by blocking calcineurin, Ras, and Ca2+/calmodulin-dependent protein kinase II signaling.
Bisserier M; Berthouze-Duquesnes M; Breckler M; Tortosa F; Fazal L; de Régibus A; Laurent AC; Varin A; Lucas A; Branchereau M; Marck P; Schickel JN; Deloménie C; Cazorla O; Soulas-Sprauel P; Crozatier B; Morel E; Heymes C; Lezoualc'h F
Circulation; 2015 Jan; 131(4):390-400; discussion 400. PubMed ID: 25369805
[TBL] [Abstract][Full Text] [Related]
6. PICOT attenuates cardiac hypertrophy by disrupting calcineurin-NFAT signaling.
Jeong D; Kim JM; Cha H; Oh JG; Park J; Yun SH; Ju ES; Jeon ES; Hajjar RJ; Park WJ
Circ Res; 2008 Mar; 102(6):711-9. PubMed ID: 18258855
[TBL] [Abstract][Full Text] [Related]
7. Calcineurin Aβ-Specific Anchoring Confers Isoform-Specific Compartmentation and Function in Pathological Cardiac Myocyte Hypertrophy.
Li X; Li J; Martinez EC; Froese A; Passariello CL; Henshaw K; Rusconi F; Li Y; Yu Q; Thakur H; Nikolaev VO; Kapiloff MS
Circulation; 2020 Sep; 142(10):948-962. PubMed ID: 32611257
[TBL] [Abstract][Full Text] [Related]
8. Calcineurin/NFAT coupling participates in pathological, but not physiological, cardiac hypertrophy.
Wilkins BJ; Dai YS; Bueno OF; Parsons SA; Xu J; Plank DM; Jones F; Kimball TR; Molkentin JD
Circ Res; 2004 Jan; 94(1):110-8. PubMed ID: 14656927
[TBL] [Abstract][Full Text] [Related]
9. Calcineurin plays a critical role in the development of pressure overload-induced cardiac hypertrophy.
Zou Y; Hiroi Y; Uozumi H; Takimoto E; Toko H; Zhu W; Kudoh S; Mizukami M; Shimoyama M; Shibasaki F; Nagai R; Yazaki Y; Komuro I
Circulation; 2001 Jul; 104(1):97-101. PubMed ID: 11435345
[TBL] [Abstract][Full Text] [Related]
10. Growth hormone-releasing hormone attenuates cardiac hypertrophy and improves heart function in pressure overload-induced heart failure.
Gesmundo I; Miragoli M; Carullo P; Trovato L; Larcher V; Di Pasquale E; Brancaccio M; Mazzola M; Villanova T; Sorge M; Taliano M; Gallo MP; Alloatti G; Penna C; Hare JM; Ghigo E; Schally AV; Condorelli G; Granata R
Proc Natl Acad Sci U S A; 2017 Nov; 114(45):12033-12038. PubMed ID: 29078377
[TBL] [Abstract][Full Text] [Related]
11. Overexpression of calmodulin induces cardiac hypertrophy by a calcineurin-dependent pathway.
Obata K; Nagata K; Iwase M; Odashima M; Nagasaka T; Izawa H; Murohara T; Yamada Y; Yokota M
Biochem Biophys Res Commun; 2005 Dec; 338(2):1299-305. PubMed ID: 16256941
[TBL] [Abstract][Full Text] [Related]
12. The Calcineurin Variant CnAβ1 Controls Mouse Embryonic Stem Cell Differentiation by Directing mTORC2 Membrane Localization and Activation.
Gómez-Salinero JM; López-Olañeta MM; Ortiz-Sánchez P; Larrasa-Alonso J; Gatto A; Felkin LE; Barton PJR; Navarro-Lérida I; Del Pozo MÁ; García-Pavía P; Sundararaman B; Giovinazo G; Yeo GW; Lara-Pezzi E
Cell Chem Biol; 2016 Nov; 23(11):1372-1382. PubMed ID: 27746127
[TBL] [Abstract][Full Text] [Related]
13. Activation of Na+/H+ exchanger 1 is sufficient to generate Ca2+ signals that induce cardiac hypertrophy and heart failure.
Nakamura TY; Iwata Y; Arai Y; Komamura K; Wakabayashi S
Circ Res; 2008 Oct; 103(8):891-9. PubMed ID: 18776042
[TBL] [Abstract][Full Text] [Related]
14. Calcineurin plays a critical role in pressure overload-induced cardiac hypertrophy.
Shimoyama M; Hayashi D; Takimoto E; Zou Y; Oka T; Uozumi H; Kudoh S; Shibasaki F; Yazaki Y; Nagai R; Komuro I
Circulation; 1999 Dec; 100(24):2449-54. PubMed ID: 10595959
[TBL] [Abstract][Full Text] [Related]
15. Enhanced expression of DYRK1A in cardiomyocytes inhibits acute NFAT activation but does not prevent hypertrophy in vivo.
Grebe C; Klingebiel TM; Grau SP; Toischer K; Didié M; Jacobshagen C; Dullin C; Hasenfuss G; Seidler T
Cardiovasc Res; 2011 Jun; 90(3):521-8. PubMed ID: 21273244
[TBL] [Abstract][Full Text] [Related]
16. Systemic heme oxygenase-1 transgenic overexpression aggravates pressure overload-induced cardiac hypertrophy in mice.
Chen C; Huo R; Tong Y; Sheng Y; Liu HB; Gao X; Nakajima O; Yang BF; Dong DL
Cell Physiol Biochem; 2011; 28(1):25-32. PubMed ID: 21865845
[TBL] [Abstract][Full Text] [Related]
17. Ginseng reverses established cardiomyocyte hypertrophy and postmyocardial infarction-induced hypertrophy and heart failure.
Moey M; Gan XT; Huang CX; Rajapurohitam V; Martínez-Abundis E; Lui EM; Karmazyn M
Circ Heart Fail; 2012 Jul; 5(4):504-14. PubMed ID: 22576957
[TBL] [Abstract][Full Text] [Related]
18. LIM and cysteine-rich domains 1 regulates cardiac hypertrophy by targeting calcineurin/nuclear factor of activated T cells signaling.
Bian ZY; Huang H; Jiang H; Shen DF; Yan L; Zhu LH; Wang L; Cao F; Liu C; Tang QZ; Li H
Hypertension; 2010 Feb; 55(2):257-63. PubMed ID: 20026769
[TBL] [Abstract][Full Text] [Related]
19. Cisapride protects against cardiac hypertrophy via inhibiting the up-regulation of calcineurin and NFATc-3.
Zhou X; Zhang Q; Zhao T; Bai X; Yuan W; Wu Y; Liu D; Li S; Ju J; Chege Gitau S; Chu W; Xu C; Lu Y
Eur J Pharmacol; 2014 Jul; 735():202-10. PubMed ID: 24769415
[TBL] [Abstract][Full Text] [Related]
20. Ablation of biglycan attenuates cardiac hypertrophy and fibrosis after left ventricular pressure overload.
Beetz N; Rommel C; Schnick T; Neumann E; Lother A; Monroy-Ordonez EB; Zeeb M; Preissl S; Gilsbach R; Melchior-Becker A; Rylski B; Stoll M; Schaefer L; Beyersdorf F; Stiller B; Hein L
J Mol Cell Cardiol; 2016 Dec; 101():145-155. PubMed ID: 27789290
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
